Richard A.  Heyman net worth and biography

Richard Heyman Biography and Net Worth

Director of PMV Pharmaceuticals
Richard A. Heyman, PhD, currently serves as Chairman and co-founder of Metacrine Inc., a biotech startup developing therapeutics for liver and gastrointestinal diseases.  He also is the co-founder and Chairman of ORIC Pharmaceuticals, which is developing drugs to overcome resistance in cancer and serves as Chairman of Amunix Pharmaceuticals and Vividion Therapeutics.  Previously, Rich was the co-founder and CEO of Aragon and Seragon Pharmaceuticals; which focused on therapeutics targeting hormone dependent cancers.  J&J purchased Aragon in 2013 and Genentech purchased Seragon in 2014.  He has been involved in the discovery and development of multiple therapeutic agents approved by the FDA, including the recently approved prostate cancer drug, Erleada. 

Rich also serves on the BOD of Gritstone Oncology and Yumanity Therapeutics.  In addition to his corporate experience, Rich is Vice Chair of the Board of Trustees at the Salk Institute, on the Board Foundation for the AACR and on the Board of Visitors at the UCSD Moores Cancer Center.  He has won numerous awards including Ernst and Young San Diego Regional Entrepreneur of the Year and the Endocrine Society Outstanding Innovation Award.  He was an NIH postdoctoral fellow and staff scientist at the Salk Institute.  Rich received a PhD in pharmacology and a BS in chemistry and is the author or inventor on more than 125 publications and patents.

What is Richard A. Heyman's net worth?

The estimated net worth of Richard A. Heyman is at least $243,899.00 as of March 19th, 2024. Dr. Heyman owns 143,470 shares of PMV Pharmaceuticals stock worth more than $243,899 as of March 29th. This net worth evaluation does not reflect any other investments that Dr. Heyman may own. Learn More about Richard A. Heyman's net worth.

How do I contact Richard A. Heyman?

The corporate mailing address for Dr. Heyman and other PMV Pharmaceuticals executives is , , . PMV Pharmaceuticals can also be reached via phone at 609-642-6670 and via email at [email protected]. Learn More on Richard A. Heyman's contact information.

Has Richard A. Heyman been buying or selling shares of PMV Pharmaceuticals?

Richard A. Heyman has not been actively trading shares of PMV Pharmaceuticals during the last ninety days. Most recently, Richard A. Heyman sold 3,900 shares of the business's stock in a transaction on Tuesday, June 1st. The shares were sold at an average price of $32.55, for a transaction totalling $126,945.00. Learn More on Richard A. Heyman's trading history.

Who are PMV Pharmaceuticals' active insiders?

PMV Pharmaceuticals' insider roster includes Leila Alland (Insider), Richard Heyman (Director), Winston Kung (CFO), Arnold Levine (Director), David Mack (CEO), and Thilo Schroeder (Director). Learn More on PMV Pharmaceuticals' active insiders.

Are insiders buying or selling shares of PMV Pharmaceuticals?

During the last twelve months, insiders at the sold shares 2 times. They sold a total of 91,890 shares worth more than $222,931.26. The most recent insider tranaction occured on November, 22nd when Major Shareholder Orbimed Advisors Llc sold 87,786 shares worth more than $195,762.78. Insiders at PMV Pharmaceuticals own 7.6% of the company. Learn More about insider trades at PMV Pharmaceuticals.

Information on this page was last updated on 11/22/2023.

Richard A. Heyman Insider Trading History at PMV Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/1/2021Sell3,900$32.55$126,945.00View SEC Filing Icon  
See Full Table

Richard A. Heyman Buying and Selling Activity at PMV Pharmaceuticals

This chart shows Richard A Heyman's buying and selling at PMV Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

PMV Pharmaceuticals Company Overview

PMV Pharmaceuticals logo
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
Read More

Today's Range

Now: $1.70
Low: $1.64
High: $1.71

50 Day Range

MA: $1.71
Low: $1.51
High: $1.93

2 Week Range

Now: $1.70
Low: $1.18
High: $9.72

Volume

643,441 shs

Average Volume

715,173 shs

Market Capitalization

$87.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66